Cargando…

Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1

Chondrosarcoma (CHS) is the second most common bone malignancy with limited therapeutic approaches. Our previous study has found that Yes associated protein 1 (YAP1) is downregulated in CHS cells treated with bromodomain and extraterminal domain (BET) inhibitor JQ1. However, the precise role of YAP1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Huan-Tian, Gui, Tao, Liu, Ri-Xu, Tong, Kui-Leung, Wu, Chong-Jie, Li, Zhenyan, Huang, Xun, Xu, Qiu-Tong, Yang, Jie, Tang, Wang, Sang, Yuan, Liu, Wanting, Liu, Ning, Ross, Ryan D., He, Qing-Yu, Zha, Zhen-Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835383/ https://www.ncbi.nlm.nih.gov/pubmed/33495462 http://dx.doi.org/10.1038/s41419-021-03416-1

Ejemplares similares

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
por: Zhao, Bei, et al.
Publicado: (2018)

Modulation of Virulence-Associated Traits in Aspergillus fumigatus by BET Inhibitor JQ1
por: Orekhova, Anastasia, et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1
por: Fujiwara, Hiroaki, et al.
Publicado: (2018)

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
por: Korb, Erica, et al.
Publicado: (2015)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
por: Benito, E, et al.
Publicado: (2017)

The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells
por: Garcia, Patrick L., et al.
Publicado: (2022)

Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer
por: Luan, Wenqing, et al.
Publicado: (2019)

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
por: Wroblewski, Mark, et al.
Publicado: (2018)

Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer
por: Yamamoto, Keisuke, et al.
Publicado: (2016)

The BET Inhibitor JQ1 Augments the Antitumor Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
por: Miller, Aubrey L., et al.
Publicado: (2021)

BET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells
por: Alghamdi, Saeed, et al.
Publicado: (2016)

BET bromodomain inhibitor JQ1 regulates spermatid development by changing chromatin conformation in mouse spermatogenesis
por: Wang, Xiaorong, et al.
Publicado: (2021)

BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling
por: Zhou, Siqi, et al.
Publicado: (2020)

Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum]
Publicado: (2019)

BET Protein Inhibitor JQ1 Modulates Mitochondrial Dysfunction and Oxidative Stress Induced by Chronic Kidney Disease
por: Rayego-Mateos, Sandra, et al.
Publicado: (2023)

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
por: Li, Zichong, et al.
Publicado: (2013)

Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo
por: Maggisano, Valentina, et al.
Publicado: (2019)

BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc
por: Li, Ning, et al.
Publicado: (2018)

Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis
por: Zhang, Meng-Yi, et al.
Publicado: (2020)

Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells
por: Bauer, Karin, et al.
Publicado: (2018)

BET inhibitor JQ1 suppresses cell proliferation via inducing autophagy and activating LKB1/AMPK in bladder cancer cells
por: Li, Feng, et al.
Publicado: (2019)

Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
por: Chan, Kwok-Ho, et al.
Publicado: (2017)

GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1
por: Kumar, Krishan, et al.
Publicado: (2015)

The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
por: Miller, Aubrey L., et al.
Publicado: (2019)

Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins by JQ1 Unravels a Novel Epigenetic Modulation to Control Lipid Homeostasis
por: Tonini, Claudia, et al.
Publicado: (2020)

BET Inhibitor JQ1 Attenuates Feline Leukemia Virus DNA, Provirus, and Antigen Production in Domestic Cat Cell Lines
por: Moll, Garrick M., et al.
Publicado: (2023)

Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1
por: Mumby, Sharon, et al.
Publicado: (2023)

The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer
por: da Motta, L L, et al.
Publicado: (2017)

MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells
por: Kato, Fuyumi, et al.
Publicado: (2016)

The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model
por: Sauvage, Delphine, et al.
Publicado: (2022)

Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
por: Djamai, Hanane, et al.
Publicado: (2021)

General mechanism of JQ1 in inhibiting various types of cancer
por: Jiang, Guojuan, et al.
Publicado: (2020)

Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
por: Song, Shumei, et al.
Publicado: (2020)

The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer’s Disease
por: Magistri, Marco, et al.
Publicado: (2016)

Up-regulation of FOXD1 by YAP alleviates senescence and osteoarthritis
por: Fu, Lina, et al.
Publicado: (2019)

Instant jqGrid
por: Manricks, Gabriel
Publicado: (2013)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
por: Yao, Weilong, et al.
Publicado: (2015)

RNA sequencing reveals distinct mechanisms underlying BET inhibitor JQ1-mediated modulation of the LPS-induced activation of BV-2 microglial cells
por: Jung, Kyoung Hwa, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uf1hd0ros6c75vb5gheui8nn13